An assembly-inducing PDC enabling the efficient nuclear delivery of nucleic acid for cancer stem-like cell suppression

Wang, Dongyuan; Tian, Yuan; Sun, Xiaofang; Wu, Yuxuan; Liu, Ruping; Zeng, Fang; Du, Jingjing; Hu, Kuan

doi:10.1039/d2nr02118h

Cited by 4 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wang et al reported the use of a 5-FU conjugated peptide (FU-NHOH(19), Scheme 7) for the delivery of nucleic acid into nucleus of cells. [22] in addition to 5-FU, 19 contains a hydroxamic acid group at the C-terminus to inhibit histone deacetylases (HDACs). The authors used 19 to coassemble with an anticancer aptamer, AS1411, which is a 26-mer guanine-rich oligonucleotide DNA in phase II clinical trials for relapsed or refractory acute myeloid leukemia and renal cell carcinoma.…”

Section: Peptides Conjugated With Anticancer Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Peptide Assemblies for Cancer Therapy

2023

ChemMedChem

View full text Add to dashboard Cite

Supramolecular assemblies made by the self‐assembly of peptides are finding an increasing number of applications in various fields. While the early exploration of peptide assemblies centered on tissue engineering or regenerative medicine, the recent development has shown that peptide assemblies can act as supramolecular medicine for cancer therapy. This review covers the progress of applying peptide assemblies for cancer therapy, with the emphasis on the works appeared over the last five years. We start with the introduction of a few seminal works on peptide assemblies, then discuss the combination of peptide assemblies with anticancer drugs. Next, we highlight the use of enzyme‐controlled transformation or shapeshifting of peptide assemblies for inhibiting cancer cells and tumors. After that, we provide the outlook for this exciting field that promises new kind of therapeutics for cancer therapy.

show abstract

Section: Peptides Conjugated With Anticancer Drugsmentioning

confidence: 99%

“…Wang et al. reported the use of a 5‐FU conjugated peptide (FU‐NHOH( 19 ), Scheme 7) for the delivery of nucleic acid into nucleus of cells [22] . in addition to 5‐FU, 19 contains a hydroxamic acid group at the C‐terminus to inhibit histone deacetylases (HDACs).…”

Section: Assemblies Of the Conjugates Of Peptide And Drugmentioning

confidence: 99%

Peptide Assemblies for Cancer Therapy

2023

ChemMedChem

View full text Add to dashboard Cite

show abstract

Recent advances in aptamer-based therapeutic strategies for targeting cancer stem cells

Liu¹,

Hu²,

Xiang³

et al. 2023

Materials Today Bio

View full text Add to dashboard Cite

Cancer stem cells: advances in knowledge and implications for cancer therapy

Chu,

Tian,

Ning

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Cancer stem cells (CSCs), a small subset of cells in tumors that are characterized by self-renewal and continuous proliferation, lead to tumorigenesis, metastasis, and maintain tumor heterogeneity. Cancer continues to be a significant global disease burden. In the past, surgery, radiotherapy, and chemotherapy were the main cancer treatments. The technology of cancer treatments continues to develop and advance, and the emergence of targeted therapy, and immunotherapy provides more options for patients to a certain extent. However, the limitations of efficacy and treatment resistance are still inevitable. Our review begins with a brief introduction of the historical discoveries, original hypotheses, and pathways that regulate CSCs, such as WNT/β-Catenin, hedgehog, Notch, NF-κB, JAK/STAT, TGF-β, PI3K/AKT, PPAR pathway, and their crosstalk. We focus on the role of CSCs in various therapeutic outcomes and resistance, including how the treatments affect the content of CSCs and the alteration of related molecules, CSCs-mediated therapeutic resistance, and the clinical value of targeting CSCs in patients with refractory, progressed or advanced tumors. In summary, CSCs affect therapeutic efficacy, and the treatment method of targeting CSCs is still difficult to determine. Clarifying regulatory mechanisms and targeting biomarkers of CSCs is currently the mainstream idea.

show abstract

An assembly-inducing PDC enabling the efficient nuclear delivery of nucleic acid for cancer stem-like cell suppression

Abstract: Nucleic acid therapy is attracting great attention in diverse clinical translations because of its therapeutic advantages. As a renowned oligonucleotide therapeutical candidate in clinical stage, AS1411 has shown outstanding tumor...

Cited by 4 publications

References 49 publications

Peptide Assemblies for Cancer Therapy

Peptide Assemblies for Cancer Therapy

Recent advances in aptamer-based therapeutic strategies for targeting cancer stem cells

Cancer stem cells: advances in knowledge and implications for cancer therapy

Contact Info

Product

Resources

About